ADCEF/ ADCEF INSTA USE

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory Only

Abbreviated Prescribing information for ADCEF [Cefdinir 300 mg capsule/125 mg/5 ml suspension] [Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: It is an extended-spectrum, semisynthetic cephalosporin. As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis.

INDICATION: Adcef is indicated for the treatment of patients with mild to moderate infections [Community-Acquired Pneumonia, Acute Exacerbations of Chronic Bronchitis, Pharyngitis/Tonsillitis, Uncomplicated Skin and Skin Structure Infections] caused by susceptible strains of microorganism. Adcef Insta indicated for Pharyngitis/Tonsillitis and Uncomplicated Skin and Skin Structure Infections in Pediatric Patients.

DOSAGE AND ADMINISTRATION: The dosing is varying among adult and adolescent for indications. Total daily dose is 600mg daily in divided dose. Patients with renal insufficiency 300mg once daily. Patients on hemodialysis 300mg or 7mg/kg administered every other day. For pediatric patients, 14 mg/kg suspension per day is recommended.

CONTRAINDICATION: Hypersensitivity to any of the components of product or to cephalosporin group antibiotics.

WARNINGS & PRECAUTIONS: Use cautiously in patients having past history of beta-lactamase resistant as cross-resistant may develop; Colitis; Renal insufficiency; Keep a gap of ~2 hours if antacid administered with cefdinir.

DRUG INTERACTIONS: Antacids (aluminum- or magnesium-containing) reduce absorption of cefdinir if used concomitantly; Probenecid inhibits renal excretion; Iron supplements and foods fortified with iron reduces absorption of cefdinir; False positive result for urine ketone if nitroprusside test used. False positive reaction for glucose in urine if Clinitest, Benedict's solution, or Fehling's solution used.

ADVERSE REACTIONS: Diarrhea, vaginal moniliasis, nausea, headache, abdominal pain, vaginitis. Incidence of adverse events <1% but >0.1% were rash, dyspepsia, flatulence, vomiting, anorexia, constipation, abnormal stools, asthenia, dizziness, insomnia, leukorrhoea, pruritis and somnolence. Serious allergic reaction including skin reactions (TEN, SJS, erythema multiforme), anaphylaxis, renal dysfunction, cholestasis, aplastic anemia, hemolytic anemia, hemorrhage, false-positive test for urinary glucose, neutropenia, pancytopenia, agranulocytosis, Pseudomembranous colitis, Triggering of seizure in patients with renal insufficiency.

MARKETED BY:

TORRENT PHARMACEUTICALS LTD.
Torrent House, Off Ashram Road,
Ahmedabad-380 009, INDIA

IN/ ADCEF/ ADCEF INSTA USE/Feb-2015/01/AbPI

(Additional information is available on request)